Barclays Raises Agilent Technologies (NYSE:A) Price Target to $150.00

Key Points

• Barclays has raised its price target for Agilent Technologies from $125.00 to $150.00, indicating a potential upside of 8.02% from the stock's previous close.
• Other research firms such as Wells Fargo and Robert W. Baird have also adjusted their target prices, reflecting a generally positive outlook on Agilent Technologies.
• The stock currently holds a consensus rating of "Moderate Buy" with an average price target of $142.17, supported by both buy and hold ratings from various analysts.

Agilent Technologies (NYSE:A - Get Free Report) had its price objective increased by equities researchers at Barclays from $125.00 to $150.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an "equal weight" rating on the medical research company's stock. Barclays's target price would indicate a potential upside of 8.02% from the stock's previous close.

A number of other research firms also recently weighed in on A. Wells Fargo & Company upped their target price on Agilent Technologies from $140.00 to $150.00 and gave the stock an "overweight" rating in a research report on Monday, September 15th. Robert W. Baird increased their target price on Agilent Technologies from $141.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, August 28th. Evercore ISI reduced their target price on Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating for the company in a report on Thursday, August 28th. Finally, Wall Street Zen lowered Agilent Technologies from a "buy" rating to a "hold" rating in a report on Friday, September 5th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $142.17.

Agilent Technologies Stock Performance

Shares of NYSE A traded up $0.29 during midday trading on Thursday, hitting $138.87. 389,912 shares of the company's stock were exchanged, compared to its average volume of 1,936,949. The firm has a market cap of $39.37 billion, a P/E ratio of 32.67, a PEG ratio of 4.19 and a beta of 1.26. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. Agilent Technologies has a twelve month low of $96.43 and a twelve month high of $153.84. The stock's 50 day moving average price is $122.00 and its 200-day moving average price is $116.17.

Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting analysts' consensus estimates of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm's revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities research analysts anticipate that Agilent Technologies will post 5.58 EPS for the current year.

Institutional Investors Weigh In On Agilent Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Agilent Technologies by 13.5% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock valued at $4,279,000 after purchasing an additional 4,362 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Agilent Technologies by 8.3% during the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock worth $3,606,000 after buying an additional 2,371 shares in the last quarter. Alps Advisors Inc. grew its position in Agilent Technologies by 29.5% during the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock worth $1,563,000 after buying an additional 3,040 shares in the last quarter. D.A. Davidson & CO. grew its position in Agilent Technologies by 30.4% during the first quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company's stock worth $1,108,000 after buying an additional 2,207 shares in the last quarter. Finally, LGT Capital Partners LTD. lifted its stake in Agilent Technologies by 7.6% during the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company's stock worth $89,870,000 after purchasing an additional 54,302 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.